Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.
Mayur M AmonkarLauren A AbderhaldenGrace E FoxAndrew M FredericksonTorkia GriraAlexander GozmanUsha MalhotraWilliam MalbecqKatherine G AkersPublished in: Future oncology (London, England) (2024)
Aim: A systematic review and meta-analysis were performed to evaluate the efficacy of treatments for previously treated advanced biliary tract cancer (BTC) patients. Materials & methods: Databases were searched for studies evaluating treatments for advanced (unresectable and/or metastatic) BTC patients who progressed on prior therapy. Pooled estimates of objective response rate (ORR), median overall survival (OS) and median progression-free survival (PFS) were calculated using random effects meta-analysis. Results: Across 31 studies evaluating chemotherapy or targeted treatment regimens in an unselected advanced BTC patient population, pooled ORR was 6.9%, median OS was 6.6 months and median PFS was 3.2 months. Conclusion: The efficacy of conventional treatments for previously treated advanced BTC patients is poor and could be improved by novel therapies.
Keyphrases
- newly diagnosed
- end stage renal disease
- free survival
- systematic review
- ejection fraction
- chronic kidney disease
- papillary thyroid
- small cell lung cancer
- peritoneal dialysis
- clinical trial
- randomized controlled trial
- case control
- locally advanced
- machine learning
- drug delivery
- case report
- young adults
- lymph node metastasis
- childhood cancer
- big data
- artificial intelligence
- bone marrow